GLUCAGON-DERIVED PEPTIDE HAVING DUAL RECEPTOR AGONISTIC ACTION AND USE THEREOF

WIPO Patent Application WO/2020/098657

A1

Provided is a polypeptide derivative having dual receptor agonistic action, a modified derivative thereof or a salt thereof, comprising a polypeptide having the sequence of the following general formula I: general formula I: HX2QGTFTSDX10SX12YLX15EX17X18AX20EFX23X24WLX27X28X29X30X31, wherein the definitions of X2, X10, X12, X15, X17, X18, X20, X23, X24, X27, X28, X29, X30 and X31 are as described in claims and description. Further provided is use of the polypeptide derivative, the modified derivative thereof, or the salt thereof. The polypeptide is a variant designed on the basis of a GC natural sequence, and produces synergistic effects on energy metabolism by means of dual agonism of GC/GLP-1 receptor, thereby effectively reducing blood sugar while reducing body weight and improving body fat levels, having more potential than a single-receptor agonist to improve conditions such as diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease.

HAN YINGMEI (CN)
LIU WEI (CN)
LIU BINGNI (CN)
ZHAO NAXIA (CN)
SHANG QIAN (CN)
XIA GUANGPING (CN)
KONG WEILING (CN)
JIN JING (CN)
KONG XIAOHUA (CN)
LI YUQUAN (CN)
GAO QI (CN)

PCT/CN2019/117614

May 22, 2020

November 12, 2019

Click for automatic bibliography generation  

TIANJIN INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN)

C07K14/605; A61K38/26; A61P1/16; A61P3/04; A61P3/10; A61P9/00; A61P25/28

WO2016209978A2	2016-12-29
WO2010096052A1	2010-08-26

CN106046145A	2016-10-26
CN108271356A	2018-07-10
EP2084182B1	2013-08-28
EP2676673B1	2016-11-16

PANAWELL & PARTNERS, LLC (CN)

View/Download PDF      PDF Help

Previous Patent: METHOD AND APPARATUS FOR DETERMINING QUASI-CO-LOCATION REFERENCE SIGNAL

Next Patent: 20-SUBSTITUTED CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF